Document:

EX-10.1

 Exhibit 10.1 

THE GYMBOREE CORPORATION  

500 Howard Street 
 San Francisco,
California 94105 
 Dear Lynda: 
 The purpose of this letter
agreement (the “Agreement”) is to set out the terms of your transition from your current role as a Senior Advisor to The Gymboree Corporation (the “Company”) to the role of interim Chief Financial Officer. The
effective date of this Agreement is July 24, 2014 (the “Effective Date”). 
  

	1.	Base Salary. During the Term (as defined below), as full compensation for all services performed by you for the Company and its affiliates, and subject to your performance hereunder, the Company will pay you
compensation at an annual rate of $375,000 (the “Base Salary”), less standard payroll deductions and withholdings. During the Term, the Base Salary shall be payable in accordance with the Company’s regular payroll schedule,
subject to your continued service to the Company through the date of the payment. 

  

	2.	Annual Bonus. You will not be eligible to receive an annual cash bonus under the Company’s annual bonus program in respect of the Company’s 2014 fiscal year or any fiscal year thereafter.

  

	3.	Position and Term. The term of this Agreement (the “Term”) will commence on the Effective Date and will end on the earlier of (i) a date following the conclusion of a transition period (not
to exceed 30 days) after the date on which a successor Chief Financial Officer of the Company has commenced employment in such role and (ii) a date specified by the Company in its sole discretion. Unless otherwise determined by the Company,
(i) you will serve as the principal financial officer of the Company through the date on which a new Chief Financial Officer is appointed and commences employment in such role and (ii) you agree to provide reasonable transition assistance
to the successor Chief Financial Officer for a period not to exceed 30 days following his or her commencement of employment in such role. 

  

	4.	Status of Employee Benefits. Throughout the Term, you and your eligible dependents will remain eligible to participate in all employee benefit plans of the Company that are made available generally to senior
executive officers of the Company, subject to the terms of such plans; provided that you will not earn vacation or other similar benefits at any time. 

  

	5.	Additional Payments. The Company will pay you a lump sum bonus at the end of each three-month period following February 1, 2015 (i.e., the first bonus would be payable on May 1, 2015), provided
that as of the date of payment you remain employed by the Company as its interim Chief Financial Officer. If you remain employed as its interim Chief Financial Officer after February 1, 2015 but you resign prior to the end of an applicable
three-month period thereafter, the Company will pay you a pro-rated portion (based on the number of days you were employed during the three-month period) of the applicable $50,000 payment within 30 days of your termination date. 

	6.	Transition Bonus. 

  

	 	a.	Although the Company is not otherwise obligated to do so, if you remain in service to the Company through the end of the Term, subject to Section 7 below, the Company will pay you a lump sum amount in cash equal to
$281,250, less standard payroll deductions and withholdings. Any bonus payable under this Section 6(a) will be paid to you not later than the 30th day following the end of the Term, subject
to the Release becoming effective prior to the date of payment. 

  

	 	b.	In the event that (i) you resign on or after August 29, 2014 but prior to the end of the Term or (ii) the Company determines that the Term shall end prior to August 29, 2014, you will not be entitled
to any payment under Section 6(a) but, subject to Section 7 below, the Company will pay you a lump sum amount in cash equal to $150,000, less standard payroll deductions and withholdings. Any bonus payable under this Section 6(b) will
be paid to you not later than the 30th day following the date your employment terminates, subject to the Release becoming effective prior to the date of payment. 

 

	7.	Release of Claims. The Company’s obligation to pay you any bonus under Section 6 above is contingent upon you timely signing and returning (and not revoking) a general release of all claims
(“Release”) in the form attached hereto as Exhibit A. You will be given 21 days to consider the Release and the Release will take effect on the eighth day following the date of your signing, provided you do not timely revoke
it by providing written notice to the Company. 

  

	8.	Return of Documents and Other Property. You agree that upon the termination of your services to the Company, you will return to the Company any and all records, documents, materials and information (whether in
hardcopy, on electronic media or otherwise) related to the business (whether present or otherwise) of the Company and its affiliates, and all keys, access cards, credit cards, computer hardware and software, telephones and telephone-related
equipment, and all other property of the Company or its affiliates in your possession or control. 

  

	9.	Withholding. The payments made by the Company under this Agreement will be reduced by all taxes and other amounts required to be withheld by the Company under applicable law and all other lawful deductions
authorized by you. 

  

	10.	Section 409A. For purposes of this Agreement, all references to “termination of employment” and correlative phrases shall be construed to require a “separation from service” (as defined in
Section 1.409A-1(h) of the Treasury regulations after giving effect to the presumptions contained therein). Each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under
this Agreement is to be treated as a right to a series of separate payments. 

  
 2 

	11.	Miscellaneous. 

  

	 	a.	Merger Clause; Severability. This Agreement contains the entire agreement between you and the Company, and supersedes all prior and contemporaneous communications, agreements and understandings, whether written
or oral, with respect to your employment, your engagement as a Senior Advisor, and the termination of such engagement. In the event that your employment with the Company terminates prior to the end of the Term, this Agreement shall terminate
immediately and become null and void in all respects. This Agreement shall not be construed strictly for or against you, the Company, Giraffe Holding, Inc. Gymboree Holding, Ltd. or any released party described in the Release. The provisions of this
Agreement are severable, which means that if any provision is held to be invalid or unenforceable, it shall not affect the validity or enforceability of any other provision. 

 

	 	b.	Amendment; Headings. This Agreement may not be modified or amended, and no breach will be deemed to be waived, unless agreed to in writing by you and the Company. The captions and headings in this Agreement are
for convenience only and in no way define or describe the scope or content of any provision of this Agreement. 

  

	 	c.	Continued Performance. The obligations of the Company to make payments to you and to provide you with benefits under this Agreement are expressly conditioned upon your continued full performance of your
obligations under this Agreement. Nothing in this Agreement shall give you the right to continue as an employee or other service provider of the Company or any of its affiliates. 

 

	 	d.	Governing Law and Venue. This Agreement is governed by the laws of the state of California. The parties agree that California courts shall have exclusive jurisdiction and venue over any claim made by any of the
parties hereunder. The parties further agree that the California courts have personal jurisdiction over the parties to this Agreement. 

[Remainder of page intentionally left blank.] 

  
 3 

 If the terms of this Agreement are acceptable to you, please promptly sign, date and return it to the General
Counsel of the Company. 
  

			
	 THE GYMBOREE CORPORATION:

	
	 /s/ Mark Breitbard

	Mark Breitbard
	Chief Executive Officer

  

			
	 Accepted and Agreed:

	
	 /s/ Lynda Gustafson

	Lynda Gustafson
	
	Date: July 18, 2014

 Exhibit A 

Release of Claims 
 In exchange
for the opportunity to earn a transition bonus as set forth in Section 6 of the letter agreement between you, The Gymboree Corporation (the “Company”) and Gymboree Holding, Ltd., dated July     , 2014 (the
“Agreement”), and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, on your own behalf and that of your heirs, executives, administrators, beneficiaries, personal representatives
and assigns, you, LYNDA GUSTAFSON, agree that this release of claims (this “Release”) shall be in complete and final settlement of any and all causes of action, rights and claims, whether known or unknown, that you have had in the
past, now have, or might now have, in any way related to, connected with or arising out of your employment or its termination or relating to employment discrimination claims (including claims of race or sex discrimination and/or sexual harassment,
and/or age) and/or retaliation under Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, 42 U.S.C. § 1981, the Age Discrimination in Employment Act, 29 U.S.C. § 626 (ADEA), the Genetic Information Nondiscrimination Act
of 2008, and all employment discrimination claims arising under any similar state and local laws (including but not limited to the California Fair Employment and Housing Act), disputed wages, or claims for any back wages or overtime, claims for
benefits (including any and all of employee benefit, fringe benefit, stock benefit, or severance-related programs, arrangements, and plans), claims for paid leave, and including claims under the Fair Labor Standards Act, the Equal Pay Act, the WARN
Act, the Employee Retirement Income Security Act of 1974 (ERISA), the California Labor Code and applicable Wage Orders, and any similar state and local laws, disability discrimination claims under the Americans with Disabilities Act, and applicable
state and local laws (including but not limited to the California Fair Employment and Housing Act), wrongful discharge and/or breach of contract claims, claims arising under the Family & Medical Leave Act or the California Family Rights
Act, tort claims, including invasion of privacy, defamation, fraud, and infliction of emotional distress and any similar state and local laws, and/or any other federal, state or local laws, regulations or other requirement, and you hereby release
and forever discharge the Company, its subsidiaries, affiliates and any direct or indirect parent (including but not limited to Giraffe Holding, Inc. and Gymboree Holding, Ltd.) or controlling companies and its subsidiaries and affiliates and all of
their past, present, and future officers, directors, trustees, shareholders, employees, employee benefit plans, agents, general and limited partners, members, managers, joint venturers, investors, representatives, successors and assigns, and all
others connected with any of them, both individually and in their official capacities, from any and all such causes of action, rights and claims. Further, you represent and warrant that you have not filed any such claim to date, nor have you
assigned any such claim to any other person or entity. 
 This Release does not waive rights or claims you may have for worker’s
compensation benefits but does include any claim for worker’s compensation discrimination under California Labor Code § 132a or otherwise. This Release also does not waive rights or claims under federal or state law that you cannot, as a
matter of law, waive by private agreement, such as a right of indemnification under California Labor Code Section 2802. Additionally, nothing in this Agreement precludes you from filing a Complaint or participating in any investigation or
proceeding before any federal or state agency, including the EEOC. However, while you may file a Complaint or participate in any proceeding conducted by a state or federal agency, 

  
 Exh. A-1 

 
by signing this Release, you waive your right to bring a lawsuit against the Company and/or any of the Released Parties and waive your right to any individual monetary recovery in any action or
lawsuit initiated by a federal or state agency, such as the EEOC. 
 RELEASE OF UNKNOWN CLAIMS: You understand and acknowledge
that this Release extinguishes all claims, whether known or unknown, foreseen or unforeseen. You expressly waive any rights or benefits under Section 1542 of the California Civil Code, which provides as follows: 

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF
KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR. 
 You fully understand that if any fact with respect to any
matter covered by this Release is found hereafter to be other than or different from the facts you now believe to be true, then you expressly accept and assume that this Release shall be and remain effective, notwithstanding the difference in the
fact or facts. 
 This Release creates legally binding obligations, and the Company therefore advises you to consult an attorney before
signing it. In signing this Release, you give the Company assurance that you have signed it voluntarily and with a full understanding of its terms; that you have had sufficient opportunity, before signing this Release, to consider its terms and to
consult with an attorney, if you wished to do so; and that, in signing this Agreement, you have not relied on any promises or representations, express or implied, from the Company or any of its affiliates. You further acknowledge that your waiver
and release do not apply to any rights or claims that may arise after the execution date of this Release. 
 If the terms of this Release
are acceptable to you, you must sign, date and return it to the General Counsel of the Company within 21 days of the date you receive it. You may revoke this Release at any time during the seven-day period immediately following the
date of your signing by written notice of such revocation to the undersigned. If you do not revoke it, then, at the expiration of that seven-day period, this Release will take effect as a legally binding agreement between you and the Company on the
basis set forth above. 
 THIS RELEASE MUST BE SIGNED AND DELIVERED TO THE GENERAL COUNSEL OF THE GYMBOREE CORPORATION BY THE DEADLINE IN THE IMMEDIATELY
PRECEDING PARAGRAPH IN ORDER FOR YOU TO RECEIVE THE PAYMENT DESCRIBED IN SECTION 6 OF THE AGREEMENT. 
  

	
	 Accepted and Agreed:

	
	  

	 Lynda Gustafson

	
	 Date:
                                        

  
 Exh. A-2EXHIBIT 10.1

 

This Post-Closing Amendment to the Asset Purchase Agreement (the “Agreement”) is entered into as of September 9, 2014, and by and among RenovaCare, Inc., a Nevada corporation (the “Parent”), RenovaCare Sciences Corp., a Nevada corporation and wholly owned subsidiary of the Parent (the “Buyer”) and Jörg Gerlach, MD, PhD, an individual having a place of residence at [•] (the “Seller”). The Parent, the Buyer and the Seller together may be referred to herein as the “Parties” and each of them may be referred to herein as a “Party.” All other capitalized terms used herein and not otherwise defined have the meaning ascribed thereto in the Original APA (as defined below).

 

RECITALS:

 

Whereas, the Parties entered into an Asset Purchase Agreement dated as of June 21, 2013 (the “Original APA”), pursuant to which Buyer agreed to purchase from the Seller and the Seller agreed to sell to the Buyer, the Cell Deposition Device, on the terms and conditions set forth in the Original APA;

 

Whereas, the Parties consummated the purchase and sale of the Cell Deposition Device, as contemplated by the Original APA, on July 12, 2013;

 

Whereas, the Parties deem it to be in their respective best interests to amend the Original APA;

 

Now Therefore, in consideration of the foregoing and of the following covenants, the sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

Section 1: Amendments. The Original APA is hereby amended as follows:

 

(a) Section 1.2.(b)(ii) is deleted in its entirety and the following inserted in lieu thereof:

 

“(ii) an aggregate of $300,000 (the “Deferred Cash Purchase Price”) payable on or before such subsequent dates (each a “Deferred Payment Date”) set forth in this Section 1.2(b).

 

(1) $100,000 on or before December 31, 2014;

 

(2) $50,000 on or before December 31, 2015;

 

(3) $50,000 on or before December 31, 2016; and

 

(4) $100,000 on or before December 31, 2017 (each payment pursuant to Section 1.2(b)(ii) shall be referred to as a “Deferred Payment”).

 

Payment of the Deferred Cash Purchase Price is further subject to Section 6.”

 

(b) The first sentence of Section 1.6. is deleted in its entirety and the following inserted in lieu thereof:

 

“Subject to Section 6, on the Deferred Payment Date Buyer shall pay the Deferred Cash Purchase Price due on such date by wire transfer of immediately available funds in accordance with the wire instructions of which Seller may notify Buyer as provided for herein.”

 

(c) Section 5.4. is hereby deleted in its entirety and the following substituted in lieu thereof:

 

“5.4. Confidential Information Effective Period. The obligations of the parties set forth in this Section 5 shall remain in effect for a period of five (5) years from the date of Closing (the “Confidential Information Effective Period”).”

 

(d) Section 6., including all subsections, is hereby deleted in its entirety and the following substituted in lieu thereof.

 

	 
	
1

	

 

“6. Cessation of Development Determination. Anything in this Agreement to the contrary notwithstanding, at any time prior to the full payment of the Cash Portion of the Purchase Price the Buyer, in its sole discretion, may elect to discontinue the development and commercialization of the Cell Deposition Device (the “Cessation of Development Determination”). In the event of a Cessation of Development Determination the Company, in its sole discretion, may choose to (i) pay all unpaid portions of the Deferred Cash Purchase Price (the “Cessation of Development Payment”), or (ii) re-convey the Buyer’s rights to the Acquired Assets to the Seller (the “Cessation of Development Re-conveyance”), as set forth below.

 

(a) Cessation of Development Payment. In the event the Buyer elects to discontinue the development and commercialization of the Cell Deposition Device and make the Cessation of Development Payment, Buyer shall provide the Seller written notice in accordance with Section 10 of its Cessation of Development Determination and shall make a wire transfer of immediately available funds to the Seller in the amount of all unpaid portions of the Deferred Cash Purchase Price (the date on which the Cessation of Development Payment is made shall be referred to as the “Cessation of Development Payment Date”). On the Cessation of Development Payment Date no further Warrant Shares shall vest pursuant to the Warrant and all vested but unexercised Warrant Shares as of the date immediately preceding the date of the Cessation of Development Payment shall be forfeited and cancelled.

 

(b) Cessation of Development Re-conveyance. In the event the Buyer elects to discontinue the development and commercialization of the Cell Deposition Device and make the Cessation of Development Re-Conveyance, Buyer shall provide the Seller written notice in accordance with Section 10 of its Cessation of Development Determination which shall include the date on which the Buyer shall re-convey the Acquired Assets to the Seller (the “Cessation of Development Re-conveyance Date”). The Cessation of Development Re-Conveyance Date shall be no later than sixty (60) days after the date on which the Buyer has provided the Seller of written notice of a Cessation of Development Determination. On the Cessation of Development Re-conveyance Date the Parties shall execute such documentation as necessary to evidence the re-conveyance of the Acquired Assets by Buyer to the Seller. The Cessation of Development Re-conveyance shall not include any enhancements, modifications or any Intellectual Property produced by the Buyer relating to the Cell Deposition Device not specifically acquired by the Buyer from the Seller pursuant to this Agreement. On the Cessation of Development Re-conveyance Date no further Warrant Shares shall vest pursuant to the Warrant and all vested but unexercised Warrant Shares as of the date immediately preceding the date of the Cessation of Development Payment shall be forfeited and cancelled. In the event of a re-conveyance pursuant to this Section 6, or Section 7.1 below, Seller shall not be responsible for any fees associated with the re-conveyance, other than for fees payable to Seller’s counsel or filing fees to the United States Patent and Trademark Office, or such other government entity, necessary to evidence the transfer of the Acquired Assets to the Seller.”

 

(e) The first sentence of Section 7.1. is hereby deleted in its entirety and the following inserted in lieu thereof:

 

“Subject to the Buyer’s rights pursuant to Section 6, if the Buyer fails to pay to the Seller the Deferred Cash Purchase Price when and as due, then in lieu of, but not in addition to any other remedies or rights that otherwise may be or may have been available hereunder to the Seller at law or in equity, the Seller shall have the right to require the Buyer to re-convey the Acquired Assets (such Re-conveyance shall not include any enhancements, modifications or any Intellectual Property produced by the Buyer relating to the Cell Deposition Device not specifically acquired by the Buyer from the Seller pursuant to this Agreement) to the Seller without the refund or return by the Seller of any portion of the Purchase Price (any such re-conveyance is herein referred to as a “Re-conveyance”).”

 

	 
	
2

	

 

(f) In the first sentence of Section 8.1., the words “six months” shall be changed to “sixteen months”.

 

(g) The first two sentences of Section 9 are hereby deleted in their entirety and the following inserted in lieu thereof:

 

“9. Non-Competition. Seller hereby acknowledges that Buyer has expended significant time and funds relating to the acquisition of the Acquired Assets from Seller. Seller hereby agrees that so long as Buyer has not forwarded Seller a Cessation of Development Determination pursuant to Section 6, but in no event after the five year anniversary of the Closing Date, so long as Buyer is not in default of its obligations under this Agreement, Seller shall not engage in the development of any Intellectual Property that would directly or indirectly infringe on, or reduce the value of, the Acquired Assets (collectively, the “Infringing Intellectual Property”).”

 

(h) The following shall be added to the end of Section 9:

 

“Anything in this Agreement to the contrary notwithstanding, nothing in this Agreement shall be interpreted to restrict in any way Seller’s work at the University of Pittsburgh (the “University”), including engaging in research activities as part of Seller’s employment by the University sponsored by any company.”

 

(i) The second paragraph of the recitals to “Exhibit 1.2-Form of Warrant” to the Original APA is deleted in its entirety and is inserted in lieu thereof:

 

“This Warrant is being issued pursuant to the terms of that certain Asset Purchase Agreement dated as of June 21, 2013 and as amended on September 9, 2014, between Company and Holder (the “Asset Purchase Agreement”). Capitalized but undefined terms used herein shall have the meaning set forth in the Asset Purchase Agreement. This Warrant supersedes and replaces the Warrant the Company issued to the Holder dated July 12, 2013. For purposes of this Warrant the closing shall be deemed to have occurred on July 12, 2013.”

 

(j) The last line of Section 12.6 is hereby deleted in its entirety.

 

(k) All references in the Original APA to other sections therein have been revised to reflect the changes made by this Agreement.

 

(l) Section 5 of “Exhibit 1.2-Form of Warrant” to the Original APA is deleted in its entirety and is inserted in lieu thereof:

 

“5. Vesting of Warrants.

 

The Shares issuable upon exercise of this Warrant in accordance with the terms hereof shall vest as follows:

 

(i) 240,000 Shares shall vest in arrears on the first anniversary date of the closing as set forth in the Asset Purchase Agreement;

 

(ii) 240,000 Shares shall vest in arrears on the second anniversary date of the closing as set forth in the Asset Purchase Agreement;

 

(iii) 240,000 Shares shall vest in arrears on the third anniversary date of the closing as set forth in the Asset Purchase Agreement;

 

(iv) 240,000 Shares shall vest in arrears on the fourth anniversary date of the closing as set forth in the Asset Purchase Agreement; and

 

	 
	
3

	

 

(v) 240,000 Shares shall vest in arrears on the fifth anniversary date of the closing as set forth in the Asset Purchase Agreement.”

 

(m) All references to “Janus Resources, Inc.” are deleted and “RenovaCare, Inc.” is inserted in lieu thereof.

 

(n) All references to “Janus Acquisition Corp.” are deleted and “RenovaCare Sciences Corp.” is inserted in lieu thereof.

 

(o) All references to “Rhonda B. Rosen” are deleted and “Thomas Bold” is inserted in lieu thereof.

 

SECTION 2. Miscellaneous.

 

(a) Counterparts. This Agreement may be executed in two or more counterparts and shall be effective when each Party has executed at least one of the counterparts even though all Parties have not executed the same counterpart. The Parties may execute this Agreement and all other agreements, certificates, instruments and other documents contemplated by this Agreement and exchange on the Closing Date counterparts of such documents by means of facsimile transmission or email and the Parties agree that the receipt of such executed counterparts shall be binding on such Parties and shall be construed as originals. After the Closing the Parties shall promptly exchange original versions of this Agreement and all other agreements, certificates, instruments and other documents contemplated by this Agreement that were executed and exchanged by facsimile transmission or email pursuant to this Section. Notwithstanding anything herein to the contrary, including the effective date of this Agreement set forth in the preamble, this Agreement shall not be effective until signed by Parent, Buyer and Seller.

 

(b) Entire Agreement. This Agreement, together with the Original APA, comprise the complete and integrated agreement of the Parties and shall supersede all prior agreements, written or oral, on the subject matter hereof. To the extent that there is any inconsistency between the Original APA and this Agreement, this Agreement shall govern. This Agreement has been drafted with the joint participation of the parties hereto and shall be construed to be neither against nor in favor of Buyer, Parent or Seller in accordance with the fair meaning thereof. Attached hereto as Exhibit A, is a cumulative conformed copy of the Original APA as amended by this Agreement.

 

(c) Interpretation. When a reference is made in this Agreement to Sections or Schedules, such reference shall be to a Section of or Schedule to this Agreement unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.”

 

(d) Severability. The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability or the other provisions hereof. If any term, covenant, restriction or provision contained in Agreement, is held by a court of competent jurisdiction to be invalid, void, against its regulatory policy or unenforceable, the remainder of the terms, provisions, covenants and restrictions contained in this Agreement shall remain valid and binding and shall in no way be affected, impaired or invalidated, so long as the economic and legal substance of the transactions contemplated hereby are not affected in any manner materially adverse to any Party. Upon such a determination, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible so that the transactions contemplated hereby can be consummated as originally contemplated to the fullest extent possible.

 

(e) Continuing Effect of the Original APA. Except as specifically amended by this Agreement the terms and conditions of the Original APA remain in full force and effect.

 

[SIGNATURES APPEAR ON THE FOLLOWING PAGE]

 

	 
	
4

	

 

In Witness Whereof, the Parties have executed this Amendment to the Original APA as of the date first above written.

 

 

	PARENT: RENOVACARE, INC.	 
	 	 	 
	By:	 /s/ Thomas Bold  	 
	Name:	Thomas Bold	 
	Title:	President and Chief Executive Officer	 
	 	 	 
	
BUYER: RENOVACARE SCIENCES CORP.

	
		 	
	By:	/s/ Thomas Bold 	
	Name:	
Thomas Bold

	
	Title:	
President

	
	 	
	SELLER: JÖRG GERLACH, MD, PHD	
		 	
	By:	/s/ Jorg Gerlach 	
	Name:	
Jörg Gerlach, MD, PhD

	

 

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]